By Donna Loyle, communications specialist, LIMR
June is Men’s Health Month, which makes this an ideal time to highlight clinical study #NRG GU005, a randomized phase III trial comparing stereotactic body radiation therapy (SBRT) to intensity-modulated radiation therapy (IMRT) in men with stage IIA-B prostate cancer.
The study seeks to determine if SBRT is superior to IMRT in terms of genitourinary and gastrointestinal toxicity. There are two study arms: One undergoes IMRT once daily over less than 32 business days. The other undergoes SBRT at least every other day over less than 12 business days. Patients then undergo follow-up care for two years.
Study #NRG GU005 approved for Lankenau Medical Center. The principal investigators are Albert DeNittis, MD, and Paul Gilman, MD. For more, email email@example.com or visit mainlinehealth.org/research/clinical-trials/nrg-gu005